Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12657)	12/16/1997 3:01:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, I did have similar questions, in part because I don't think that there would or could be a dual pricing structure. The same drug could cost a different amount in different forms (oral or topical), but I would think that the price of a 400 mg pill would be the same, regardless of the application (although a 400 mg pill could cost less than two 200 mg pills). As the population size of the appproved indication changes, I could see the cost coming down (the compounds could actually be manufactured for very reasonable cost, i.e. on a par with Viatmins), but I find it hard to envision a dual pricing structure, especially for off-label use (but of course none of the above is in my area of expertise).